Horizon Therapeutics Inc v. Par Pharmaceutical Inc, No. 2:14-cv-00384 (E.D. Tex. Oct. 20, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Defendant Par Pharmaceutical, Inc. filed an Abbreviated New Drug Application (“ANDA”) seeking the FDA’s approval to market a generic version of Plaintiff Horizon Therapeutics, Inc.’s drug Ravicti. Par’s ANDA filing gave rise to this patent infringement dispute. On August 12, 2015, the Court held a hearing to determine the proper construction of nine disputed terms in two asserted patents: U.S. Patent No. 8,404,215 (“the ’215 patent”) and U.S. Patent No. 8,642,012 (“the ’012 patent”).